Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
Top Cited Papers
- 1 June 2001
- journal article
- clinical trial
- Published by Elsevier BV in The Lancet
- Vol. 357 (9271), 1842-1847
- https://doi.org/10.1016/s0140-6736(00)04954-0
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesionsJournal of the American Academy of Dermatology, 2000
- Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritisArthritis & Rheumatism, 2000
- Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitisGastroenterology, 1999
- IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach.JCI Insight, 1998
- Aetiology and pathogenesis of psoriasisBritish Journal of Dermatology, 1996
- Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functionsCytokine, 1995
- Construction and initial characterization of a mouse-human chimeric anti-TNF antibodyMolecular Immunology, 1993
- The immunology of psoriasisBritish Journal of Dermatology, 1992
- Tumor necrosis factorJournal of the American Academy of Dermatology, 1991
- Severe Psoriasis – Oral Therapy with a New RetinoidDermatology, 1978